Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma
出版年份 2023 全文链接
标题
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2023-01-31
DOI
10.1200/jco.22.02197
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Booster BNT162b2 Optimizes SARS-CoV-2 Humoral Response in Myeloma Patients; the Negative Effect of anti-BCMA therapy
- (2022) Evangelos Terpos et al. BLOOD
- The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint
- (2022) Nicholas C Richardson et al. LANCET ONCOLOGY
- T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
- (2022) Nora Zieger et al. BLOOD
- Teclistamab in Relapsed or Refractory Multiple Myeloma
- (2022) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
- (2022) Anita D'Souza et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
- (2022) Nizar Jacques Bahlis et al. BLOOD
- Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study
- (2022) Naresh Bumma et al. BLOOD
- Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
- (2022) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
- (2021) Suzanne Trudel et al. BLOOD
- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
- (2020) Luciano J. Costa et al. BLOOD
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Reporting infections in clinical trials of patients with haematological alignancies – A systematic review
- (2019) Noam Tau et al. CLINICAL MICROBIOLOGY AND INFECTION
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
- (2014) P. G. Richardson et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search